In particular, we conclude that CMIS is a condition more and more frequently diagnosed with no significant impact on life expectancy: accordingly, its relevance is mainly linked to the clinical [22, 62] and pathologic [21, 63, 64] difficulty in making a differential diagnosis with invasive melanoma. Although their enrollment in screening programs for the early detection of skin melanoma is warranted because of the risk of developing invasive melanoma, patients diagnosed with CMIS should be reassured on the benign nature of their condition that is associated with a normal life expectancy. Finally, the fact that CMIS increasing incidence does not nullify the positive trend regarding the prognosis of invasive melanoma and the fact that an in situ tumor is associated with a lower risk of some invasive cancers deserves further attention and investigation.
It’s really strange that people with CMIS have a lower risk of some other cancers. . I hope early invasive thin melanomas don’t have a significant impact on life expectancy either. . I know it’s not 100% 5 year, but it’s high 90s I think (< 0.5mm)
Viewing 3 posts - 1 through 3 (of 3 total)
The forum ‘Melanoma: Newly Diagnosed – Stages I & II’ is closed to new topics and replies.